Wednesday, September 15, 2021 at 10am EDTDrug manufacturing demands and increased regulatory oversight are prompting pharmaceutical manufacturers to consider new processes for oral solid dose and aseptically processed drugs. A cross-section of industry experts will offer insight on emerging trends, technologies, and processes in this Technology Forum.
This article presents the results of a survey conducted to gain insight on the impact of the COVID-19 pandemic on biomanufacturing operations.
By taking a digital maturity-first approach to Pharma 4.0, manufacturers can optimally position themselves for success.
The industry considers applying automation and digitalization lessons learned during the COVID-19 pandemic to enhance workflows.
October 4, 2021 at 3pm BST | 10am EST | 4pm CEST Join global industry and regulatory experts as they discuss current hot topics in extractables and leachables (E&L) testing for pharmaceuticals, biopharmaceuticals and medical devices.
FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Innovations in downstream processing accelerate development, enhance efficiency, and promote sustainability.
What do you need to ask during the vetting and selection process to ensure your clinical or commercial program won’t be derailed by a quality-related problem?
Webinar Date/Time: Tue, Sep 26, 2023 11:00 AM EDT
Explore top affinity resins for efficient downstream bioprocessing and lower costs.
This case study examines the benefits and challenges Nephron Pharmaceuticals Corporation faced integrating a STERIS VHP® Biodecontamination system into their high-volume compounding facility.
A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
In part 2 of this article, results from the testing of a next generation convecdiff membrane are discussed.
Creativity and collaboration are required to overcome complex method development challenges.
Webinar Date/Time: Thu, Jun 20, 2024 10:00 AM EDT
The authors evaluated the potential of direct filtration for multiple biopharmaceutical candidates. This article is Part 2 of the study.
Biopharmaceutical production faces the challenge of ensuring the quality of raw materials due to a lack of specific guidelines. By implementing effective risk assessment strategies and working with reliable, selected solution providers, biopharmaceutical manufacturers can minimize these challenges and improve product quality.
Continuous SEC was shown to increase productivity with the same product quality and yield.
Many biologic drug manufacturers encounter similiar challenges; precompetitive collaboration can help resolve these issues. Representatives of the IQ Consortium’s Biologics CMC Leadership Group describe efforts to address the safe handling of biologic drugs in closed-system transfer devices in healthcare settings and the need for phase-appropriate specifications.
Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.
Guest contributor Frederic Kahn discusses the state of the Indian pharmaceutical manufacturing industry.
A step-by-step path to building confidence in packaging component selection for injectable drugs
Process development methods & analytical requirements are integral parts of gene therapy manufacturing. This whitepaper explores the analytical and development approaches needed for success.
Gene therapy products present a unique set of challenges for the control of host cell protein impurities.
Ongoing and emerging cyber-risks to legacy operational technology systems in bio/pharmaceutical manufacturing must be addressed.
Assessment of peripheral blood protein glycosylation has recently become scalable, providing a new domain for biomarker research.
In this article, a simple chromatographic model is proposed that is capable of predicting the impact of pH and ionic strength on HIC chromatograms.
Start-ups are plagued with common issues that dramatically decrease their odds of achieving investor funding.
A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis